Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goldhirsch

Showing results (471-480 of 753) with videos related to

Pageof 76
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2012
Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trialsJ Huober, S Gelber, A Goldhirsch, et al.
Cancer|December 15, 1986
Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasisB W Davis, R D Gelber, A Goldhirsch, et al.
European Journal of Cancer & Clinical Oncology|August 1, 1982
A quality control study to assess the inter-laboratory variability of routine estrogen and progesterone receptor assaysD T Zava, A Wyler-von Ballmoos, A Goldhirsch, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 21, 1999
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patientsM E Sabbioni, M Castiglione, C Hürny, et al.
Immunotherapy|April 26, 2014
Dendritic cell-based vaccines: clinical applications in breast cancerLucia Gelao, Carmen Criscitiello, Angela Esposito, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2005
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effectsM Colleoni, L Orlando, G Sanna, et al.
Cancer Chemotherapy and Pharmacology|July 20, 2007
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expressionAndrea Rocca, Giuseppe Viale, Richard D Gelber, et al.
Breast Cancer Research and Treatment|January 30, 2007
Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centreChiara Catania, Gilda Ascione, Laura Adamoli, et al.
Breast (Edinburgh, Scotland)|February 21, 2012
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumabSilvia Dellapasqua, Vincenzo Bagnardi, Francesco Bertolini, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2013
High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapyS Zurrida, V Bagnardi, G Curigliano, et al.
Pageof 76

Showing results (471-480 of 753) with videos related to

Sort By:
Pageof 76
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2012
Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trialsJ Huober, S Gelber, A Goldhirsch, et al.
Cancer|December 15, 1986
Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasisB W Davis, R D Gelber, A Goldhirsch, et al.
European Journal of Cancer & Clinical Oncology|August 1, 1982
A quality control study to assess the inter-laboratory variability of routine estrogen and progesterone receptor assaysD T Zava, A Wyler-von Ballmoos, A Goldhirsch, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 21, 1999
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patientsM E Sabbioni, M Castiglione, C Hürny, et al.
Immunotherapy|April 26, 2014
Dendritic cell-based vaccines: clinical applications in breast cancerLucia Gelao, Carmen Criscitiello, Angela Esposito, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2005
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effectsM Colleoni, L Orlando, G Sanna, et al.
Cancer Chemotherapy and Pharmacology|July 20, 2007
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expressionAndrea Rocca, Giuseppe Viale, Richard D Gelber, et al.
Breast Cancer Research and Treatment|January 30, 2007
Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centreChiara Catania, Gilda Ascione, Laura Adamoli, et al.
Breast (Edinburgh, Scotland)|February 21, 2012
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumabSilvia Dellapasqua, Vincenzo Bagnardi, Francesco Bertolini, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2013
High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapyS Zurrida, V Bagnardi, G Curigliano, et al.
Pageof 76